Brief: Solvonis Therapeutics Initiates Studies For SVN-002 To Support 505(B)(2) Pathway And Advance Towards Phase 2B Trial
22/07/2025 07:47
July 22 (Reuters) - Solvonis Therapeutics PLC SVNS.L: SOLVONIS THERAPEUTICS PLC - INITIATES STUDIES FOR SVN-002 TO SUPPORT 505(B)(2) PATHWAY AND ADVANCE TOWARDS PHASE 2B TRIAL Source text: ID:nRSV9498Ra Further company coverage: SVNS.L ((( Reuters.Briefs@thomsonreuters.com );))